highlight top-read differenti piec march provid
updat view feedback highlight includ feedback celg lbo analysi
markman scoop aldr ceo transit trump/azar drug price overhang
celg drl reach surpris compromis markman believ revlimid settlement like
celg trap valu -- lbo analysi markman scoop note gain traction
among investor month leverag buy-out scenario analysi celg -- show signific
roi opportun modest premium win-win-win scenario sharehold compani
purchas see continu opportun upsid come month potenti
inflect add detail ozanimod rtf call clinic catalyst luspatercept
revlimid bd commerci execut potenti gener settlement anoth top-read note
first-to-market scoop celg/drl agreement forgo markman on-going revlimid anda
litig view increas likelihood potenti settlement gener
aldr ceo transit follow surpris departur aldr founder ceo randi schatzman
opportun discuss board move current management includ newly-appoint
interim ceo paul cleveland well former ceo stock weak event
predic bla time concern believ unlik materi issu caus
transit see note rather believ follow schatzman success posit
compani clinic financi legal front board randi agre new ceo could help
usher aldr next chapter commercially-ori compani see allevi bla time
concern follow compani earn call believ timelin potenti
reiter lack reiter stem primarili cautiou approach new interim
ceo gain familiar compani intern oper
trump drug price rhetor could overhang though like impact
drug price overhang march saw renew concern drug price overhang continu
keep generalist sidelin -- theme eb flow perhap contribut
neg sentiment march anticip trump/azar plan potenti hh reform
tba mid-april view overhang like persist line
outlook believ investor toler polit headlin continu increas draconian
congression action unlik gain muster potenti chang measured/low impact
focus pbm renew action avx could draw generalist back
sector look toward nvs/avx tender offer file gaug investor enthusiasm/pharma appetit
actual anticip transact
top-read/most differenti note march includ
highlight visit manag biktarvi launch high gear nash easl data
takeaway chicago day car-t cf ms
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
takeaway merg lane bcrx/idra manag
ms franchis continu hold tight despit competit push pull
adjust model base recent ms alzheim stroke develop
trump drug price rhetor could overhang though like impact
celg drl reach surpris compromis markman believ revlimid
view competit data ozanimod maintain lead
takeaway chicago day car-t cf ms
enter busi heplisav-b launch asco data
highlight visit manag biktarvi launch high gear nash easl data
expect seamless manag transit norbert bischofberg step
cf updat trial start soon broad studi plan
noteworthi wkli script trends/forecast keep tab biktarvi
noteworthi wkli script trends/forecast keep tab biktarvi
noteworthi wkli script trends/forecast keep tab biktarvi
noteworthi wkli script trends/forecast tab biktarvi symdeko
limit read-through rtf continu upsid
expect continu momentum selinexor readout increas
biotech lit bit review interest literatur scienc
guidanc re-affirmed sma pipelin data year
assembl next-gen cf pipelin worth watch initi outperform
clinic hold compet microdystrophin program increment posit
march toward golo-lin drive toward expand dmd franchis
